亿帆医药创新药F-627在美定价4600美元/支

Core Viewpoint - The innovative drug F-627 from the company is priced at $4,600 per unit in the U.S., which is approximately 14 times higher than its price of 2,388 yuan per unit in China, where it has been included in the national medical insurance catalog [1] Group 1: Product Information - F-627 is the world's first third-generation long-acting G-CSF white blood cell booster and has been approved for sale in China, the U.S., the EU, and Brazil [1] - The U.S. partner, Acrotech, has recently increased the agreed procurement volume and sales targets for F-627 in the U.S. market [1] Group 2: Market Strategy - Acrotech plans to independently undertake research and development investments for the Ryzneuta® auto-injector study, aiming to further enhance its market share in the U.S. [1]